Inrebic

Product manufactured by Celgene Corporation

Application Nr Approved Date Route Status External Links
NDA212327 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Inrebic ® Is Indicated For The Treatment Of Adult Patients With Intermediate-2 Or High-Risk Primary Or Secondary (Post-Polycythemia Vera Or Post-Essential Thrombocythemia) Myelofibrosis (Mf). Inrebic Is A Kinase Inhibitor Indicated For The Treatment Of Adult Patients With Intermediate-2 Or High-Risk Primary Or Secondary (Post-Polycythemia Vera Or Post-Essential Thrombocythemia) Myelofibrosis (Mf) ( 1 ).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Fedratinib Hydrochloride

Comments